Trial Profile
Risk of Major Bleeding Associated With Apixaban Verses Warfarin in the Treatment of Venous Thromboembolism in US Clinical Practice
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 02 Mar 2022
Price :
$35
*
At a glance
- Drugs Apixaban (Primary) ; Warfarin (Primary)
- Indications Venous thromboembolism
- Focus Therapeutic Use
- Sponsors Bristol-Myers Squibb
- 10 Feb 2022 Status changed from active, no longer recruiting to completed.
- 01 Nov 2018 Results published in the Thrombosis and Haemostasis
- 15 May 2018 New trial record